Short Interest in Tcr2 Therapeutics Inc (NASDAQ:TCRR) Grows By 39.7%

Tcr2 Therapeutics Inc (NASDAQ:TCRR) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totalling 725,700 shares, a growth of 39.7% from the June 15th total of 519,400 shares. Based on an average trading volume of 113,300 shares, the days-to-cover ratio is presently 6.4 days. Currently, 6.0% of the company’s stock are short sold.

Several equities research analysts have commented on the company. SVB Leerink reissued an “outperform” rating on shares of Tcr2 Therapeutics in a report on Monday, March 30th. BidaskClub raised Tcr2 Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 24th. ValuEngine downgraded Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Tcr2 Therapeutics in a report on Tuesday, June 23rd. Finally, Wedbush reaffirmed an “outperform” rating on shares of Tcr2 Therapeutics in a report on Monday, March 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.50.

Shares of NASDAQ:TCRR traded down $0.76 during midday trading on Tuesday, reaching $15.33. 2,933 shares of the company’s stock traded hands, compared to its average volume of 181,202. The company has a market cap of $374.38 million, a price-to-earnings ratio of -7.17 and a beta of 1.88. Tcr2 Therapeutics has a one year low of $5.84 and a one year high of $21.06. The stock has a 50 day moving average of $13.50 and a 200 day moving average of $12.30.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). Equities research analysts anticipate that Tcr2 Therapeutics will post -2.49 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. ArrowMark Colorado Holdings LLC boosted its stake in Tcr2 Therapeutics by 7.3% during the first quarter. ArrowMark Colorado Holdings LLC now owns 1,362,653 shares of the company’s stock valued at $10,547,000 after buying an additional 92,887 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Tcr2 Therapeutics by 0.4% in the 1st quarter. BlackRock Inc. now owns 893,928 shares of the company’s stock valued at $6,919,000 after purchasing an additional 3,888 shares during the last quarter. EcoR1 Capital LLC bought a new stake in shares of Tcr2 Therapeutics in the 4th quarter valued at approximately $3,420,000. JPMorgan Chase & Co. lifted its stake in shares of Tcr2 Therapeutics by 8.8% in the 1st quarter. JPMorgan Chase & Co. now owns 225,501 shares of the company’s stock valued at $1,745,000 after purchasing an additional 18,197 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Tcr2 Therapeutics by 22.0% during the 4th quarter. State Street Corp now owns 203,352 shares of the company’s stock worth $2,904,000 after acquiring an additional 36,718 shares during the last quarter. Hedge funds and other institutional investors own 59.22% of the company’s stock.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: Understanding Specialty Certificates of Deposit

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.